Cyclooxygenase 2 (COX-2)

Where the papers sit

37 papers from the last 6 months study Cyclooxygenase 2 (COX-2) directly · updated from PubMed 6 Oct 2026

• COX-2 Inhibitor Discovery

  COX-2 inhibitor discovery is shifting toward structurally diverse compounds with predicted selectivity and additional therapeutic targets. Molecular docking, machine learning and immobilized-enzyme screening recur alongside synthesis and IC50 testing of chalcones, hydrazones, thiohydantoins, scalaranes and natural-product derivatives. Several programs deliberately combine COX-2 inhibition with PARP-1, MetAP-2, cholinesterases or carbonic anhydrases for cancer, neurologic and inflammatory indications. In vivo and histopathologic validation remains less developed than chemical design, leaving selectivity, potency and translational benefit open.

  13 papers · 35.1%

• COX-2 in Immune Regulation

  COX-2/PGE2 signaling is being positioned as an immune-regulatory target in cancer, arthritis, osteoarthritis and inflammatory metabolic or neurologic disease. In lung adenocarcinoma, PGE2-driven NK-cell reprogramming links the pathway to acquired immunotherapy resistance, while TNBC and postoperative tumor models test combination immunomodulation. Nanoplatforms, hydrogels and PROTACs aim to localize or reprogram COX-2 activity, including macrophage polarization and cartilage repair. The broader immune-inflammatory mechanisms are recurrent, but disease-specific efficacy and safety remain open.

  12 papers · 32.4%

• Traditional Medicine and Inflammation

  Traditional formulas and plant extracts are being mapped to anti-inflammatory activity across ulcerative colitis, COPD, IBD, obesity and fatigue. LC-MS/MS, chromatography and pharmacodynamic comparisons connect candidate constituents with IL-1β, IL-6 and COX-2 changes. A recurring direction is toward multi-target control of arachidonic-acid metabolism, ferroptosis and inflammatory signaling rather than single compounds. Evidence remains mainly preclinical, and the active quality markers and tissue-specific mechanisms are still unresolved.

  7 papers · 18.9%

• Oxidative Lipid Inflammation

  Arachidonic-acid metabolism is being connected to oxidative stress and lipid peroxidation across colitis, neuroinflammation, depression, ovarian cancer and photoaging. The ACSL4/COX-2 axis, ROS, NRF2 and inflammatory cytokines recur as candidate links between membrane-lipid damage and tissue injury. Studies are moving beyond descriptive inflammation toward molecular subtypes and pathway-based intervention, including aspirin and antioxidant compounds. Whether suppressing lipid peroxidation consistently improves disease outcomes, and how cancer-specific lipid subtypes affect treatment response, remains unresolved.

  5 papers · 13.5%